Search

GSK’s RSV vaccine, Arexvy, accepted under Priority Review in US for the prevention of RSV disease in adults aged 50-59 at increased risk

Media

GSK is the first company to file for regulatory approval to extend RSV vaccination to adults aged 50-59 at increased risk.

https://www.gsk.com/en-gb/media/press-releases/arexvy-accepted-under-priority-review-in-us-for-the-prevention-of-rsv-disease-in-adults-aged-50-59-at-increased-risk/

First published: 06 February 2024

New data for Arexvy, GSK’s RSV vaccine, show potential to help protect adults aged 50 to 59 at increased risk for RSV disease

Media

Preliminary results from phase III trial show primary endpoints met, with non-inferior immune responses observed in adults aged 50-59.

https://www.gsk.com/en-gb/media/press-releases/new-data-for-arexvy-show-potential-to-help-protect-adults-aged-50-to-59/

First published: 25 October 2023

Japan’s Ministry of Health, Labour and Welfare approves GSK’s Arexvy, the country’s first respiratory syncytial virus (RSV) vaccine for older adults

Media

Arexvy’s approval will help protect adults 60 years of age and older in Japan from RSV disease for the first time

https://www.gsk.com/en-gb/media/press-releases/japan-s-ministry-of-health-labour-and-welfare-approves-gsk-s-arexvy/

First published: 25 September 2023

Japan’s Ministry of Health, Labour and Welfare accepts Arexvy (RSV vaccine) regulatory application to prevent RSV disease in adults aged 50-59 at increased risk

Media

Submission supported by positive results of a Phase III study showing immune response and safety in adults aged 50-59.

https://www.gsk.com/en-gb/media/press-releases/japan-accepts-arexvy-regulatory-application-to-prevent-rsv-disease-in-adults-aged-50-59/

First published: 12 December 2023

Gsk Rdday Part2 Vaccines Dr Moncef Slaoui Final

Media

https://www.gsk.com/media/8209/gsk-rdday-part2-vaccines-dr-moncef-slaoui_-final.pdf

First published: 06 June 2022

RSV Sympo 2025 Curtain Raiser PR

Media

https://www.gsk.com/media/11877/rsv-sympo-2025_curtain-raiser-pr.pdf

First published: 06 March 2025

RSV Sympo 2025 Curtain Raiser

Media

https://www.gsk.com/media/11878/rsv-sympo-2025-curtain-raiser.pdf

First published: 07 March 2025

Randd Day Vaccines Session

Media

https://www.gsk.com/media/8207/randd-day-vaccines-session.pdf

First published: 06 June 2022

Martin Andrews Presentation (1)

Media

https://www.gsk.com/media/8263/martin-andrews-presentation-1.pdf

First published: 06 June 2022

Breakout 1 - Seasonal respiratory viruses

Media

https://www.gsk.com/media/10376/20230620-evnt-id23-bos10-edited.pdf

First published: 28 June 2023